Phase III Multicenter Placebo-Controlled Study of Tamsulosin in Benign Prostatic Hyperplasia

Lepor, H.

doi:10.1016/s0022-5347(01)62631-4

Cited by 77 publications

(122 citation statements)

References 0 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…Alf did not cause any sexual dysfunction, while Tam, as reported in several previous studies, caused retrograde ejaculation in 14% of patients [23,24]. Recent clinical findings have suggested that alpha-blockers cause retrograde ejaculation owing to their effect on semen formation and/or transport rather than their effect on urethral smooth muscle relaxation [25].…”

Section: Discussionmentioning

confidence: 64%

Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasia

Karadağ

Öner²,

Budak

et al. 2011

Int Urol Nephrol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 64%

Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasia

Karadağ

Öner²,

Budak

et al. 2011

Int Urol Nephrol

View full text Add to dashboard Cite

show abstract

“…In 2 weiteren Studien wurden Tamsulosin-Dosen von 0,4 und 0,8 mg/Tag mit Placebo verglichen [14,15]. In diesen Studien war die Wirksamkeit beider Tamsulosin-Dosen ähnlich, aber bei 0,8 mg/Tag zeigte sich eine geringfügig reduzierte Verträglichkeit gegenüber 0,4 mg/Tag Tamsulosin oder Placebo.…”

Section: Tamsulosinunclassified

α1-Rezeptorenblockade zur Therapie des BPH-Syndroms Richtige Dosierung für optimale Wirkung

Berges

Michel²,

Jonas

2002

Urologe [A]

View full text Add to dashboard Cite

Four alpha 1-adrenoceptor antagonists are currently available for the medical treatment of lower urinary tract symptoms suggestive of benign prostatic obstruction in Germany: alfuzosin, doxazosin, tamsulosin, and terazosin. Indirect comparison based on randomized, placebo-controlled trials as well as several direct comparative studies have shown equal efficacy of all four drugs on urinary flow and symptom relief if suggested dosing regimens are applied. A dosing regimen below this recommendation should be restricted to those patients who have a proven satisfactory response to a lower dose.

show abstract

“…Previously viewed as independent processes, these diseases frequently associate and significantly impact overall quality of life for men [2,3]. Almost all accepted therapies for LUTS (surgical or medical) can impact some aspect of sexual health, and treatments for SD can also affect LUTS [4,5]. The current literature describing the interplay of LUTS and SD predominantly focuses on erectile dysfunction (ED) but can also relate to ejaculatory dysfunction (EJD) [5].…”

Section: Introductionmentioning

confidence: 99%

Lower urinary tract symptoms, benign prostatic hyperplasia, and sexual dysfunction

Park¹,

Köhler²,

McVary

2008

Curr Bladder Dysfunct Rep

View full text Add to dashboard Cite

Previously viewed as independent processes, sexual dysfunction (SD) and lower urinary tract symptoms (LUTS) frequently associate and signifi cantly detract from overall quality of life for men. Analysis of historic and emerging literature using some of the Bradford-Hill criteria argues causality between the two disease processes, with most data focusing on the interplay between LUTS and erectile dysfunction. Understanding of the relationship between SD and LUTS is crucial given the current societal age demographics leading to an increased pool of affected patients. Additional information on risk factors for either disease could potentially improve patient screening, and many currently available treatments (medical and surgical) for SD impact LUTS and vice versa.

show abstract

Phase III Multicenter Placebo-Controlled Study of Tamsulosin in Benign Prostatic Hyperplasia

Cited by 77 publications

References 0 publications

Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasia

Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasia

α1-Rezeptorenblockade zur Therapie des BPH-Syndroms Richtige Dosierung für optimale Wirkung

Lower urinary tract symptoms, benign prostatic hyperplasia, and sexual dysfunction

Contact Info

Product

Resources

About